Treating ADT patients with E2 may elicit similar effects by promoting cellular function while suppressing the growth of AR-driven cancers such as renal and prostate cancer, as shown in Figure 1, bolstering their immune systems, and promoting cellular homeostatic mechanisms which could eventually lead to symptoms similar to menopause. This evidence concerns the gene AR and prostate carcinoma.